Bulletin of Experimental Biology and Medicine

, Volume 162, Issue 4, pp 483–487 | Cite as

Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases

  • T. Yu. Dolgikh
  • N. P. Domnikova
  • Yu. V. Tornuev
  • E. V. Vinogradova
  • Yu. M. Krinitsyna
Article

Pathomorphological study of trephinobiopsy specimens from 129 patients with lymphoproliferative and myeloproliferative diseases was carried out over the course of chemotherapy. Combinations of initial and manifest myelofibrosis (loose network of reticulin fibers and extensive network of reticulin and collagen fibers, respectively) predominated at the debut of chronic myeloid leukemia, chronic lymphoid leukemia, and multiple myeloma. Manifest myelofibrosis was detected in patients with chronic myeloid leukemia without hematological response (failure of normalization of hematological values) and in patients with progressing and relapsing multiple myeloma. Combinations of foci of initial and manifest myelofibrosis were most incident in patients with progressing and relapsing chronic lymphoid leukemia. The incidence of myelofibrosis was higher in patients with multiple myeloma and chronic lymphoid leukemia progression and relapses and in patients with chronic myeloid leukemia without hematological response than at the disease debut and in case of response to chemotherapy. The response to chemotherapy in patients with chronic myeloid leukemia and chronic lymphoid leukemia was associated with a decrease in the incidence of myelofibrosis. In patients with multiple myeloma responding to chemotherapy, the incidence of myelofibrosis did not change in comparison with the disease debut.

Key Words

myelofibrosis chronic myeloid leukemia multiple myeloma chronic lymphoid leukemia trephinobiopsy specimens 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abdulkadurov KM, Abdullaev AO, Avdeeva LB, Afanas’ev BV, Vinogradova EYu, Vinogradova OYu, Volkova SA, Glonina NN, Gluzhina EV, Golenkov AK, Gusarova GA, Domracheva EV, Dubov SK, Zaklyakova LV, Zaritskii AYu, Ivanova VL, Krinitsyna EE, Kuznetsova SV, Kuz’mina LA, Kutsev SI, Kuchma GB, Lazareva OV, Lomaia EG, Martynkevich IS, Matveeva LF, Morozova EV, Pepelyaeva VM, Rusakov MN, Sudarikov AB, Turkina AG, Fominykh MS, Khoroshko ND, Tsaur GA, Chelusheva EYu, Shuvaev VA, Shukhov OA. Federal Clinical Recommendations for the diagnosis and therapy of chromic myeloid leukemia. Vestn. Gematol. 2013;9(3):4-41. Russian.Google Scholar
  2. 2.
    Dolgikh TYu, Kachesov IV, Marchenko AA, Domnikova NP. Clinical and pathomorphological examination of myelofibrosis in chronic myeloid leukemia. Sib. Onkol. Zh. 2015;(6):39-45. Russian.Google Scholar
  3. 3.
    Domnikova NP, Dolgikh TY, D’yachkova YA, Maltseva NA, Kachesov IV, Marchenko AA. Study of clinical and laboratory significance of myelofibrosis in multiple myeloma. Sib. Nauch. Med. Zh. 2014;34(6):76-81. Russian.Google Scholar
  4. 4.
    Dyachkova YuA, Dolgikh TYu, Domnikova NP. Clinico-pathomorphological study of myelofibrosis in multiple myeloma. Sib. Onkol. Zh. 2014;(3):34-38. Russian.Google Scholar
  5. 5.
    Clinical Oncohematology. Volkova MA, ed. Moscow, 2007. Russian.Google Scholar
  6. 6.
    Mendeleeva LP, Votyakova OM, Pokrovskaya OS, Rekhtina IG, Bessmel’tsev SS, Golubeva ME, Darskaya EI, Zagoskina TP, Zinina EE, Kaplanov KD, Konstantinova TS, Kryuchkova IV, Medvedeva NV, Motorin SV, Pospelova TI, Ryzhko VV, Samoilova OS, Urnova ES, Savchenko VG. National clinical guidelines for the diagnosis and treatment of multiple myeloma. Gematol. Transfusiol. 2014;59(S3):2-24. Russian.Google Scholar
  7. 7.
    Dolgikh TJ, Domnikova NP, Kachesov IV, Marchenko AA. Patent RF No. 2552928. Method of Automated Morphometric Myelofibrosis Diagnostics. Bull. No. 16. Published June 10, 2015.Google Scholar
  8. 8.
    Russian Clinical Guidelines for the Diagnosis and Treatment of Lymphoproliferative Diseases. Poddubnoi IV, Savchenko VG, eds. Moscow, 2013. Russian.Google Scholar
  9. 9.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk. Res. 2013;37(2):214-220.Google Scholar
  11. 11.
    Ribatti D, Moschetta M, Vacca A. Microenvironment and multiple myeloma spread. Thromb. Res. 2014;133(Suppl. 2):S102-S106.CrossRefPubMedGoogle Scholar
  12. 12.
    Tadmor T, Shvidel L, Aviv A, Ruchlemer R, Bairey O, Yuklea M, Herishanu Y, Braester A, Rahimi-Levene N, Vernea F, Ben-Ezra J, Bejar J, Polliack A.; Israeli CLL Study Group. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications. Cancer. 2013;119(10):1853-1859.CrossRefPubMedGoogle Scholar
  13. 13.
    Thiele J, Kvasnicka HM, Beelen DW, Flucke U, Spoer C, Paperno S, Leder LD, Schaefer UW. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients. Mod. Pathol. 2001;14(2):129-138.CrossRefPubMedGoogle Scholar
  14. 14.
    Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • T. Yu. Dolgikh
    • 1
  • N. P. Domnikova
    • 1
  • Yu. V. Tornuev
    • 1
  • E. V. Vinogradova
    • 1
  • Yu. M. Krinitsyna
    • 1
  1. 1.Institute of Molecular Pathology and PathomorphologyNovosibirskRussia

Personalised recommendations